Parmax Pharma

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE240T01014
  • NSEID:
  • BSEID: 540359
INR
135.10
0.00 (0.00%)
BSENSE

Nov 20

BSE+NSE Vol: 5.33 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Vaishali Pharma
Parmax Pharma
Concord Drugs
Tyche Industries
Denis Chem Lab
Alpa Laboratorie
Mercury Labs
Pharmaids Pharma
Cian Healthcare
Amwill Health
Vilin Bio Med
Why is Parmax Pharma Ltd ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
  • Poor long term growth as Net Sales has grown by an annual rate of 1.09% and Operating profit at 6.65% over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.66
2
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 323.51%, its profits have risen by 129% ; the PEG ratio of the company is 0.8
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Parmax Pharma for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Parmax Pharma
323.51%
4.22
76.74%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
1.09%
EBIT Growth (5y)
-207.17%
EBIT to Interest (avg)
0.66
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.77
Sales to Capital Employed (avg)
2.44
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
-28.89%
ROE (avg)
5.12%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
88
Industry P/E
24
Price to Book Value
-15.11
EV to EBIT
-27.61
EV to EBITDA
-45.73
EV to Capital Employed
21.99
EV to Sales
3.77
PEG Ratio
0.76
Dividend Yield
NA
ROCE (Latest)
-97.46%
ROE (Latest)
Negative BV
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

22What is working for the Company
NET SALES(Latest six months)

Higher at Rs 19.92 cr

PAT(Latest six months)

Higher at Rs 2.37 cr

-4What is not working for the Company
OPERATING CF(Y)

Lowest at Rs -2.36 Cr

NON-OPERATING INCOME(Q)

is 1,323.53 % of Profit Before Tax (PBT

Loading Valuation Snapshot...
Here's what is working for Parmax Pharma
Net Sales - Latest six months
At Rs 19.92 cr has Grown at 345.64%
Year on Year (YoY)
MOJO Watch
Sales trend is very positive

Net Sales (Rs Cr)

Profit After Tax (PAT) - Latest six months
At Rs 2.37 cr has Grown at 183.45%
Year on Year (YoY)
MOJO Watch
PAT trend is very positive

PAT (Rs Cr)

Net Sales - Latest six months
Higher at Rs 19.92 cr
than preceding 12 month period ended Sep 2026 of Rs 12.11 cr
MOJO Watch
In the half year the company has already crossed sales of the previous twelve months

Net Sales (Rs Cr)

Profit After Tax (PAT) - Latest six months
Higher at Rs 2.37 cr
than preceding 12 month period ended Sep 2026 of Rs -4.15 cr
MOJO Watch
In the half year the company has already crossed PAT of the previous twelve months

PAT (Rs Cr)

Here's what is not working for Parmax Pharma
Operating Cash Flow - Annually
Lowest at Rs -2.36 Cr and Fallen
each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (Rs Cr)

Non Operating Income - Quarterly
is 1,323.53 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model

Non Operating Income to PBT